Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 97Terminated 22Recruiting 18Unknown 14Active not recruiting 10Not yet recruiting 3Withdrawn 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2Thoracic 1Genitourinary 1

Conditions

Pancreatic Neoplasms 27Carcinoma, Non-Small-Cell Lung 15Neoplasms 6Lung Neoplasms 6Cholangiocarcinoma 6Carcinoma, Hepatocellular 5Sarcoma 4Neoplasm Metastasis 4Bone Neoplasms 4Recurrence 3Ovarian Neoplasms 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma 3Histiocytoma, Malignant Fibrous 3Dermatofibrosarcoma 3Biliary Tract Neoplasms 3Adenocarcinoma 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Sarcoma, Synovial 2Rhabdomyosarcoma 2Neoplasms, Unknown Primary 2Lymphoma, T-Cell 2Lymphoma, B-Cell 2Liposarcoma 2Leiomyosarcoma 2Hodgkin Disease 2Hemangiosarcoma 2Gallbladder Neoplasms 2Fallopian Tube Neoplasms 2

Interventions

Paclitaxel 28Trastuzumab 22Cyclophosphamide 21Doxorubicin 14Docetaxel 14Carboplatin 11exemestane 10Radiotherapy 10Letrozole 10Capecitabine 10pembrolizumab 8Lapatinib 8Fulvestrant 8Neoadjuvant Therapy 6Goserelin 6Bevacizumab 6Anastrozole 6pertuzumab 5palbociclib 5eribulin 5abemaciclib 5Therapeutics 5Magnetic Resonance Spectroscopy 5Epirubicin 5Chemotherapy, Adjuvant 5Aromatase Inhibitors 5tucatinib 4Vinorelbine 4Taxes 4Tamoxifen 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Breast Neoplasms × Gemcitabine × Clear all
NCT02538432 2019-11-04

Phase II Trial of EP4 Receptor Antagonist, AAT-007 (RQ-07; CJ-023,423) in Advanced Solid Tumors

University of Maryland, Baltimore

Phase 2 Withdrawn
BreastGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Prostatic Neoplasms, Disease Progression

NCT00005614 2012-09-25

Management of Metastatic Breast Cancer in Frail Patients

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Withdrawn
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡